Tiziana Life Sciences Ltd at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Hi, everyone. This is Yuan Zhi from B. Riley Securities. Thank you for joining our CNS & Ophthalmology Conference today. We will get started with our next fireside chat with Tiziana Life Sciences. Here with me today is Mr. Shailubhai, CEO and the CSO of the company. Shailubhai, thank you so much for being here with us today. Let's start by discussing the Tiziana headline broadly enabling monoclonal antibodies to yield oral, nasal and inhaled formulations. So first, can you start to give an overview of the platform, and then we can dive into the latest update of your autoimmune headlines led by the ongoing multiple sclerosis Phase 1 to nasal foralumab study.
Thank you, Yuan. It's a pleasure to be with you. I enjoy the fireside chat with B. Riley. And I think it's a great platform. And I must tell you that I'm excited to be with you because a lot of things have happened in Tiziana Life Sciences. And also, it's been a challenging year and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
